Evidence map›Paper›PMID 27651926›Full record

ArticleRMD open2016

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis.

Shannon R Sweeney, Arthur Kavanaugh, Alessia Lodi, Bo Wang, David Boyle, Stefano Tiziani, Monica Guma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Metabolomics: A Viable Approach to Understand the Pathogenesis of Reactive ArthritisEndocrine, metabolic & immune disorders drug targets · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Towards Personalized Medicine in Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2024
    Review
  9. Article
  10. Article
  11. Review
  12. A Key Metabolic Regulator of Bone and Cartilage Health.Endocrinology and metabolism (Seoul, Korea) · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shannon R SweeneyDepartment of Nutritional Sciences , Dell Pediatric Research Institute, University of Texas at Austin , Austin, Texas , USA.
Arthur KavanaughDivision of Rheumatology, Allergy and Immunology , UC San Diego School of Medicine , La Jolla, California , USA.
Alessia LodiDepartment of Nutritional Sciences , Dell Pediatric Research Institute, University of Texas at Austin , Austin, Texas , USA.
Bo WangDepartment of Nutritional Sciences , Dell Pediatric Research Institute, University of Texas at Austin , Austin, Texas , USA.
David BoyleDivision of Rheumatology, Allergy and Immunology , UC San Diego School of Medicine , La Jolla, California , USA.
Stefano TizianiDepartment of Nutritional Sciences , Dell Pediatric Research Institute, University of Texas at Austin , Austin, Texas , USA.
Monica GumaDivision of Rheumatology, Allergy and Immunology , UC San Diego School of Medicine , La Jolla, California , USA.
The University of Texas at Austin · USUniversity of California, San Diego · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Choline kinase: a novel target for rheumatoid arthritisK08AR064834 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUMA, MONICA · 2013 to 2017
$687k
Choline metabolites as biomarkers in rheumatoid arthritisR03AR068094 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUMA, MONICA · 2015 to 2018
$233k
NCI NIH HHS P30 CA054174NIAMS NIH HHS K08 AR064834NIAMS NIH HHS R03 AR068094
6 · The paper itself

Abstract

objectiveTo determine whether characterisation of patients' metabolic profiles, utilising nuclear magnetic resonance (NMR) and mass spectrometry (MS), could predict response to rituximab therapy. 23 patients with active, seropositive rheumatoid arthritis (RA) on concomitant methotrexate were treated with rituximab. Patients were grouped into responders and non-responders according to the American College of Rheumatology improvement criteria, at a 20% level at 6 months. A Bruker Avance 700 MHz spectrometer and a Thermo Scientific Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer were used to acquire (1)H-NMR and ultra high pressure liquid chromatography (UPLC)-MS/MS spectra, respectively, of serum samples before and after rituximab therapy. Data processing and statistical analysis were performed in MATLAB. 14 patients were characterised as responders, and 9 patients were considered non-responders. 7 polar metabolites (phenylalanine, 2-hydroxyvalerate, succinate, choline, glycine, acetoacetate and tyrosine) and 15 lipid species were different between responders and non-responders at baseline. Phosphatidylethanolamines, phosphatidyserines and phosphatidylglycerols were downregulated in responders. An opposite trend was observed in phosphatidylinositols. At 6 months, 5 polar metabolites (succinate, taurine, lactate, pyruvate and aspartate) and 37 lipids were different between groups. The relationship between serum metabolic profiles and clinical response to rituximab suggests that (1)H-NMR and UPLC-MS/MS may be promising tools for predicting response to rituximab.

Indexed as

InflammationLipidsRheumatoid ArthritisTreatment

Identifiers

PMID27651926
PMCPMC5013418
OpenAlexW2509989912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.